AVE 25.0% 0.5¢ avecho biotechnology limited

Irrespective of whether propofol use is growing in minimally...

  1. 5,733 Posts.
    lightbulb Created with Sketch. 15924
    Irrespective of whether propofol use is growing in minimally invasive surgery, if the aim is to grab market share with a new, improved formulation of propofol, then ideally, you would want that formulation to be substitutable for propofol in any setting.

    Even if Terumo had forged ahead with development, it was never AVE’s intention that TPM/propofol would be restricted to the Japanese market. Once the product was developed, AVE was aiming to license it out into other markets, especially the U.S.

    What matters most at this time is that the new formulation passes toxicology.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $15.84M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $189.4K 37.93M

Buyers (Bids)

No. Vol. Price($)
47 96459006 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 44667162 21
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 11.1 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 18998000
Last updated 15.25pm 29/03/2024 ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.